Registry for Asthma Characterization and Recruitment 2 (RACR2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02513264 |
Recruitment Status :
Completed
First Posted : July 31, 2015
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Asthma |
The overall goal of the Registry for Asthma Characterization and Recruitment 2 (RACR2) is to create a database of participants who are potentially eligible for future Inner City Asthma Consortium (ICAC) clinical research studies. The registry will provide an avenue to assess various asthma and allergy characteristics, which will result in more efficient recruitment for current and future ICAC protocols.
Potential participants will be recruited via telephone or in person. Those deemed potentially eligible for a current protocol or protocol in development may be invited to the clinic for further data collection and assessments. This registry allows flexibility in selecting the eligibility criteria and data collection to match planned or upcoming ICAC protocols. At each stage of data collection, participants may be discontinued, put on hold, or invited to participate in further screening activities, depending on the likelihood that they will qualify for a future protocol. Participants may opt to withdraw their information or discontinue from the registry at any time, in person, by telephone, or in writing.
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 1384 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 7 Years |
Official Title: | Registry for Asthma Characterization and Recruitment 2 (ICAC-25) |
Study Start Date : | April 14, 2015 |
Actual Primary Completion Date : | March 13, 2020 |
Actual Study Completion Date : | March 13, 2020 |
- Number of participants with asthma and allergy characteristics [ Time Frame: Year 7 ]Characteristics of the participants enrolled in the registry will be assessed on a periodic basis (descriptive summary of diagnosis and parameters associated with the former).
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 55 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Eligibility criteria vary depending on recruitment needs for future ICAC protocols. Participants with asthma and participants without asthma, atopy, and rhinitis may be recruited at the same time or different times, depending on recruitment needs.
Certain characteristics or groups of characteristics within each criterion may be selected for periods of time across clinical sites or at each individually participating clinical site. For example, over a 6-month period, the Consortium could decide to recruit children aged 6 through 12 years with diagnosed asthma who have asthma symptoms, have a history of an asthma exacerbation, and reside in prespecified census tracts within the metropolitan statistical area. During selective recruitment periods, individuals who meet broader criteria may or may not be enrolled at the discretion of the Consortium.
- All participants must resides within the metropolitan statistical area that includes the clinical site.
-
Participants with asthma are defined by having evidence of asthma. Evidence of asthma is defined by meeting at least one of the following criteria:
- Clinician-diagnosed asthma
- Asthma symptoms, history of an asthma exacerbation, or current use of asthma medication(s)
- Recurrent wheezing
- Wheezing apart from a cold
At times of selective recruitment, participants with asthma may be required to meet more selective criteria above and may be required to meet one or more of the criteria in risk factors for asthma. Evidence of risk factors for asthma is defined by meeting at least one of the following criteria:
- Parental history of asthma
- Eczema or atopic dermatitis
- Reported allergies to pets, food, indoor allergens, or outdoor allergens
- Allergic sensitization by results of allergy skin testing or results of serum immunoglobulin E (IgE) testing
- Rhinitis
-
Participants without asthma, atopy, and rhinitis must meet all of the following:
- Negative history of an asthma diagnosis by a clinician
- Negative history of a diagnosis of atopic dermatitis or eczema by a clinician
- Negative history of a rhinitis diagnosis by a clinician
- A forced expiratory volume at 1 second (FEV1) >= 5% predicted
- Negative prick skin-tests to any of a panel of indoor and outdoor allergens
- No current asthma as determined by the appropriate case report form
- No current chronic rhinitis/sinusitis as determined by the appropriate case report form
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from enrollment:
- Has any of the following chronic medical conditions: cardiac condition requiring daily medication, seizure disorder requiring daily medication, obvious severe mental retardation that prevents the participant from answering questions or following instructions, cystic fibrosis, immune deficiency, type 1 diabetes, allergic bronchopulmonary aspergillosis, or any other chronic medical condition at the discretion of the registry clinician
- Does not primarily speak English (or Spanish at clinical sites with Spanish-speaking staff)
- Has a primary caretaker who does not speak English (or Spanish at clinical sites with Spanish-speaking staff; not applicable if participant is able to provide consent)
- Is a foster child (not applicable if participant is able to provide consent)
- Is unwilling to sign the written informed consent form if of age, or parent/legal guardian is unwilling to sign the written informed consent if participant is not of age
- Is unwilling to sign the assent form, if age appropriate
Participants who are pregnant will not be excluded or discontinued from RACR2 but will not undergo any procedures that are prohibited during pregnancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02513264
United States, Colorado | |
Children's Hospital Colorado | |
Aurora, Colorado, United States, 80045 | |
United States, District of Columbia | |
Children's National Medical Center | |
Washington, District of Columbia, United States, 20010 | |
United States, Illinois | |
Ann and Robert Lurie Children's Hospital of Chicago | |
Chicago, Illinois, United States, 60611 | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21205 | |
United States, Massachusetts | |
Boston Medical Center | |
Boston, Massachusetts, United States, 02118 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 | |
United States, Missouri | |
St. Louis Children's Hospital | |
Saint Louis, Missouri, United States, 63110 | |
United States, New York | |
Columbia University Medical Center | |
New York, New York, United States, 10032 | |
United States, Ohio | |
Cincinnati Children's Hospital | |
Cincinnati, Ohio, United States, 452229 | |
United States, Texas | |
University of Texas Southwestern Medical School | |
Dallas, Texas, United States, 75390 |
Principal Investigator: | Jacqueline Pongracic, M.D. | Ann & Robert H Lurie Children's Hospital of Chicago | |
Principal Investigator: | Edward M. Zoratti, M.D. | Henry Ford Hospital |
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT02513264 |
Other Study ID Numbers: |
DAIT ICAC-25 |
First Posted: | July 31, 2015 Key Record Dates |
Last Update Posted: | January 25, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Registry Asthma Inner City Asthma Consortium (ICAC) study eligibility |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |